Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.

Dawei Chen Hampartsoum B BarsoumianGrant FischerLiangpeng YangVivek VermaAhmed I YounesYun HuFatemeh MasropourKatherine KleinChristopher VellanoJoseph MarszalekMichael A DaviesMaria Angelica CortezJames Welsh

Published in: Journal for immunotherapy of cancer (2021)

OXPHOS inhibition as part of a combinatorial regimen with XRT is a promising strategy to address PD-1-resistant NSCLC, and this combination is being tested clinically.

Keyphrases

small cell lung cancer
early stage
radiation therapy
advanced non small cell lung cancer
protein kinase
combination therapy
epidermal growth factor receptor
tyrosine kinase